Helix BioPharma Corp (HBPCF)
0.1377
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Helix BioPharma Net Income (Quarterly): -0.9232M for Oct. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| October 31, 2023 | -0.9232M |
| July 31, 2023 | -1.613M |
| April 30, 2023 | -0.9859M |
| January 31, 2023 | -0.8787M |
| October 31, 2022 | -1.207M |
| July 31, 2022 | -1.076M |
| April 30, 2022 | -1.061M |
| January 31, 2022 | -1.593M |
| October 31, 2021 | -1.442M |
| July 31, 2021 | -2.254M |
| April 30, 2021 | -2.027M |
| January 31, 2021 | -1.936M |
| October 31, 2020 | -0.1679M |
| July 31, 2020 | -1.527M |
| April 30, 2020 | -1.811M |
| January 31, 2020 | -1.695M |
| October 31, 2019 | -1.645M |
| July 31, 2019 | -1.632M |
| April 30, 2019 | -1.555M |
| January 31, 2019 | -1.432M |
| October 31, 2018 | -1.058M |
| July 31, 2018 | -1.234M |
| April 30, 2018 | -1.686M |
| January 31, 2018 | -2.027M |
| October 31, 2017 | -1.841M |
| Date | Value |
|---|---|
| July 31, 2017 | -0.9381M |
| April 30, 2017 | -2.190M |
| January 31, 2017 | -1.963M |
| October 31, 2016 | -2.508M |
| July 31, 2016 | -2.010M |
| April 30, 2016 | -1.686M |
| January 31, 2016 | -1.622M |
| October 31, 2015 | -1.969M |
| July 31, 2015 | -1.699M |
| April 30, 2015 | -1.458M |
| January 31, 2015 | -2.289M |
| October 31, 2014 | -1.923M |
| July 31, 2014 | -1.668M |
| April 30, 2014 | -1.907M |
| January 31, 2014 | -2.463M |
| October 31, 2013 | -2.059M |
| July 31, 2013 | -1.855M |
| April 30, 2013 | -2.186M |
| January 31, 2013 | 4.702M |
| October 31, 2012 | -2.106M |
| July 31, 2012 | -1.822M |
| April 30, 2012 | -2.883M |
| January 31, 2012 | -9.259M |
| October 31, 2011 | -3.239M |
| July 31, 2011 | -2.654M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-2.254M
Minimum
Jul 2021
-0.1679M
Maximum
Oct 2020
-1.415M
Average
-1.560M
Median
Net Income (Quarterly) Benchmarks
| Acasti Pharma Inc | -2.391M |
| Aurinia Pharmaceuticals Inc | -26.88M |
| Edesa Biotech Inc | -1.861M |
| Lexaria Bioscience Corp | -0.6495M |
| Xenon Pharmaceuticals Inc | -47.93M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 0.9217M |
| EPS Diluted (Quarterly) | -0.0074 |
| Enterprise Value | 30.41M |
| Earnings Yield | -19.75% |